Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer
Objective To assess the safety and tolerability of a st and ardized 40 mg red clover isoflavone dietary supplement ( Promensil ® , Novogen ) in women with a family history of breast cancer to evaluate the feasibility of using the supplement for prevention of breast cancer in healthy women . Study design Healthy women aged 35–70 years ( n = 401 ) with at least one first-degree relative with breast cancer received red clover isoflavones or placebo for three years in a r and omized , double-blind , placebo-controlled pilot trial . Participants were assessed clinical ly and blood sample s taken for biochemical analysis every six months . In addition , study participants underwent mammography , bone density and transvaginal ultrasound ( postmenopausal women only ) once per year . Results No significant differences in breast density , endometrial thickness , serum cholesterol , follicle stimulating hormone levels and bone mineral density were detected between those taking red clover isoflavones and placebo . In postmenopausal women , some significant differences in bone marker levels were seen between active and placebo groups , at six months and at 12 months . The adverse event profile was similar across all red clover isoflavone and placebo groups . Conclusion This three-year study supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women . Supplements containing red clover isoflavones did not adversely affect breast density , skeletal strength or cardiovascular status . In postmenopausal women , endometrial status was not adversely affected . The adverse event profile was similar between red clover isoflavones , and placebo and endocrine status did not differ
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .